Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Development of Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Other: standard antenatal careBehavioral: lifestyle intervention
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 552
- Registration Number
- NCT02617693
- Locations
- 🇲🇾
Novo Nordisk Investigational Site, Seremban, Negeri Sembilan, Malaysia
Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency
Phase 2
Completed
- Conditions
- Growth Hormone DisorderGrowth Hormone Deficiency in Children
- Interventions
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 74
- Registration Number
- NCT02616562
- Locations
- 🇦🇹
Landeskrankenhaus Villach, Villach, Austria
🇫🇷Hôpital Necker, Paris, France
🇸🇪Astrid Lindgrens Barnsjukhus, Stockholm, Sweden
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 48
- Registration Number
- NCT02612844
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- Other: No treatment given
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 9999
- Registration Number
- NCT02608853
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Princeton, New Jersey, United States
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1864
- Registration Number
- NCT02607865
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wellingborough, United Kingdom
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 819
- Registration Number
- NCT02607306
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yamato-shi, Kanagawa, Japan
A Trial to Investigate Different Needle Features Assessed by Comparing Insulin Aspart Pharmacokinetic Profiles
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 46
- Registration Number
- NCT02594033
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
Phase 4
Completed
- Conditions
- DiabetesType 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2019-06-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 437
- Registration Number
- NCT02582242
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Ternopil, Ukraine
Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)
Completed
- Conditions
- Growth DisorderGrowth Hormone Deficiency in Children
- Interventions
- Other: No treatment given
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 252
- Registration Number
- NCT02580032
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom
Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)
Completed
- Conditions
- HaemostasisHaemophilia BCongenital Bleeding Disorder
- Interventions
- Other: No treatment given
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2016-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 449
- Registration Number
- NCT02568202
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Plainsboro, New Jersey, United States
© Copyright 2025. All Rights Reserved by MedPath